<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460405</url>
  </required_header>
  <id_info>
    <org_study_id>Typhoid 0218</org_study_id>
    <nct_id>NCT03460405</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants</brief_title>
  <official_title>Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Indonesian Adults, Adolescents, Children and Infants (Phase II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent,&#xD;
      children and infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe the safety of this vaccine following one dose immunization in adults, adolescent,&#xD;
      children and infants.&#xD;
&#xD;
      To assess immunogenicity following one dose of Vi-DT vaccine immunization. To compare the&#xD;
      safety and immunogenicity of Vi-DT to Vi polysaccharide vaccine in adults, adolescents, and&#xD;
      children groups.&#xD;
&#xD;
      To compare the safety and immunogenicity of Vi-DT to IPV vaccine in infants groups.&#xD;
&#xD;
      Kinetics of Vi-specific IgG antibodies up to 6 months and 1 year after administration of 1&#xD;
      dose of vaccine.&#xD;
&#xD;
      To evaluate the safety and immunogenicity of Vi-DT co-administered with MR vaccine in infants&#xD;
      (≥ 9months -23 months old).&#xD;
&#xD;
      To evaluate the safety and immunogenicity of MR vaccine co-administered with Vi-DT vaccine in&#xD;
      infants (≥ 9months -23 months old).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subject aged 2 - 40 years old:&#xD;
Randomized, observer-blind, superiority design compared to Vi polysaccharide vaccine.&#xD;
Subject aged 6-23 months old:&#xD;
Randomized, observer-blind, superiority design compared to Inactivated Poliomyelitis Vaccine (IPV).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subject aged 2 - 40 years old:&#xD;
Randomized, observer-blind, superiority design compared to Vi polysaccharide vaccine.&#xD;
Subject 6-23 months old:&#xD;
Randomized, observer-blind, superiority design compared to Inactivated Poliomyelitis Vaccine (IPV).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local reaction and systemic event after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with at least one immediate reaction (local reaction or systemic event) after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events after vaccination</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Percentage of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after 1 dose vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subjects with serious adverse event from inclusion until 28 day after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT)</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric Mean Titers (GMT) 28 days following immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with increasing antibody titer &gt;= 4 times</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with increasing antibody titer &gt;= 4 times in all subjects</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Safety Issues</condition>
  <condition>Immunogenicity</condition>
  <arm_group>
    <arm_group_label>VI-DT vaccine (adults,adolescent)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml Vi-DT vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi polysaccharide (adults,adolescent)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml Vi polysaccharide vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-DT vaccine (children)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml Vi-DT vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi polysaccharide vaccine (children)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml Vi polysaccharide vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-DT vaccine (infants)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml Vi-DT vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPV Vaccine (infants)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml IPV vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi-DT Vaccine</intervention_name>
    <description>1 dose of Vi-DT Vaccine</description>
    <arm_group_label>VI-DT vaccine (adults,adolescent)</arm_group_label>
    <arm_group_label>VI-DT vaccine (children)</arm_group_label>
    <arm_group_label>VI-DT vaccine (infants)</arm_group_label>
    <other_name>Typhoid Conjugate Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi Polysaccharide Vaccine</intervention_name>
    <description>1 dose of Vi Polysaccharide Vaccine</description>
    <arm_group_label>Vi polysaccharide (adults,adolescent)</arm_group_label>
    <arm_group_label>Vi polysaccharide vaccine (children)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPV Vaccine</intervention_name>
    <description>1 dose of IPV Vaccine</description>
    <arm_group_label>IPV Vaccine (infants)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy&#xD;
&#xD;
          2. Subjects/Parents have been informed properly regarding the study and signed the&#xD;
             informed consent form&#xD;
&#xD;
          3. Subject/parents/legal guardians will commit themselves to comply with the instructions&#xD;
             of the investigator and the schedule of the trial.&#xD;
&#xD;
        Exclusion Criteria For adults-adolescent-children:&#xD;
&#xD;
          1. Subject concomitantly enrolled or scheduled to be enrolled in another trial&#xD;
&#xD;
          2. Evolving mild, moderate or severe illness, especially infectious diseases or fever&#xD;
             (axillary temperature ³ 37.5°C)&#xD;
&#xD;
          3. Known history of allergy to any component of the vaccines&#xD;
&#xD;
          4. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular&#xD;
             injection&#xD;
&#xD;
          5. Subject who has received in the previous 4 weeks a treatment likely to alter the&#xD;
             immune response (intravenous immunoglobulins, blood-derived products, corticosteroid&#xD;
             therapy and other immunosuppresant).&#xD;
&#xD;
          6. Any abnormality or chronic disease which according to the investigator might interfere&#xD;
             with the assessment of the trial objectives&#xD;
&#xD;
          7. Pregnancy &amp; lactation (Adults)&#xD;
&#xD;
          8. Individuals who have previously received any vaccines against typhoid fever.&#xD;
&#xD;
          9. Subjects already immunized with any vaccine within 1 month prior and expect to receive&#xD;
             other vaccines within 1 month following immunization.&#xD;
&#xD;
         10. Individuals who have a previously ascertained typhoid fever within 3 months prior to&#xD;
             immunization.&#xD;
&#xD;
         11. History of substance abuse (Adults).&#xD;
&#xD;
         12. Subject planning to move from the study area before the end of study period.&#xD;
&#xD;
        Exclusion Criteria for infants:&#xD;
&#xD;
          1. Subject concomitantly enrolled or scheduled to be enrolled in another trial&#xD;
&#xD;
          2. Mother less than 18 years of age at the age of enrollment of the infant&#xD;
&#xD;
          3. Evolving mild, moderate or severe illness, especially infectious diseases or fever&#xD;
             (axillary temperature ³ 37.5°C)&#xD;
&#xD;
          4. Known history of allergy to any component of the vaccines&#xD;
&#xD;
          5. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular&#xD;
             injection&#xD;
&#xD;
          6. Subject who has received in the previous 4 weeks a treatment likely to alter the&#xD;
             immune response (intravenous immunoglobulins, blood-derived products, corticosteroid&#xD;
             therapy and other immunosuppresant).&#xD;
&#xD;
          7. Any abnormality or chronic disease which according to the investigator might be&#xD;
             compromised by the vaccination and/or interfere with the assessment of the trial&#xD;
             objectives.&#xD;
&#xD;
          8. Individuals who have previously received any vaccines against typhoid fever.&#xD;
&#xD;
          9. Subjects already immunized with any vaccine within 1 month prior and expect to receive&#xD;
             other vaccines within 1 month following immunization, except MR vaccine.&#xD;
&#xD;
         10. Individuals who have a previously ascertained typhoid fever within 3 months prior to&#xD;
             immunization.&#xD;
&#xD;
         11. Subject planning to move from the study area before the end of study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernie Endyarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, University of Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Puskesmas Jatinegara</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puskesmas Senen</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 4, 2018</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

